[
  {
    "ts": null,
    "headline": "Building A $100,000 Dividend Portfolio: Maximizing SCHD's Income With July's Top High-Yield Stocks",
    "summary": "SCHD underperformed the S&P 500 in 2025 but remains highly attractive due to its strong risk-reward profile and dividend growth potential. See more here.",
    "url": "https://finnhub.io/api/news?id=62111ff39abfd05d68d3375b8580d015752f8dfee556c62d124dce3105ba7bfb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752516000,
      "headline": "Building A $100,000 Dividend Portfolio: Maximizing SCHD's Income With July's Top High-Yield Stocks",
      "id": 135931105,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209908358/image_2209908358.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "SCHD underperformed the S&P 500 in 2025 but remains highly attractive due to its strong risk-reward profile and dividend growth potential. See more here.",
      "url": "https://finnhub.io/api/news?id=62111ff39abfd05d68d3375b8580d015752f8dfee556c62d124dce3105ba7bfb"
    }
  },
  {
    "ts": null,
    "headline": "Merck (NYSE:MRK) Partners With Gates Foundation For HIV PrEP Trials In 16 Countries",
    "summary": "Merck (NYSE:MRK) recently announced the initiation of its Phase 3 EXPrESSIVE clinical trials for MK-8527, a new HIV prevention drug, reflecting its commitment to addressing global health challenges. Over the past quarter, the company’s stock saw a price increase of 6%. Despite a flat broader market largely unaffected by geopolitical trade uncertainties, Merck's progress in clinical trials and the partnership with the Gates Foundation might have provided additional optimism among investors...",
    "url": "https://finnhub.io/api/news?id=32508680c40aeeed286e1b954f9f83a0b36b72e790d9cfc8cd5d7d72cb30cc33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752513646,
      "headline": "Merck (NYSE:MRK) Partners With Gates Foundation For HIV PrEP Trials In 16 Countries",
      "id": 135936979,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) recently announced the initiation of its Phase 3 EXPrESSIVE clinical trials for MK-8527, a new HIV prevention drug, reflecting its commitment to addressing global health challenges. Over the past quarter, the company’s stock saw a price increase of 6%. Despite a flat broader market largely unaffected by geopolitical trade uncertainties, Merck's progress in clinical trials and the partnership with the Gates Foundation might have provided additional optimism among investors...",
      "url": "https://finnhub.io/api/news?id=32508680c40aeeed286e1b954f9f83a0b36b72e790d9cfc8cd5d7d72cb30cc33"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Acquire Verona for $10 Billion, Targeting Life Beyond Keytruda",
    "summary": "The deal includes a newly approved COPD treatment that could exceed $3 billion in annual revenue.",
    "url": "https://finnhub.io/api/news?id=6aa00bc0079bbf42f3f0570c8387cbbb2843acc1ca109e515d6b5cd898f0500c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752513270,
      "headline": "Merck to Acquire Verona for $10 Billion, Targeting Life Beyond Keytruda",
      "id": 135936980,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The deal includes a newly approved COPD treatment that could exceed $3 billion in annual revenue.",
      "url": "https://finnhub.io/api/news?id=6aa00bc0079bbf42f3f0570c8387cbbb2843acc1ca109e515d6b5cd898f0500c"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Merck, Monarch Cement and Team",
    "summary": "MSFT, BABA, and MRK headline today's top analyst picks, with AI, global e-commerce, and oncology driving mixed growth stories.",
    "url": "https://finnhub.io/api/news?id=1f612f532f54528079a4aa06dccd1689ae05397a05587c9af0aaa1568af2381a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752506280,
      "headline": "The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Merck, Monarch Cement and Team",
      "id": 135936981,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MSFT, BABA, and MRK headline today's top analyst picks, with AI, global e-commerce, and oncology driving mixed growth stories.",
      "url": "https://finnhub.io/api/news?id=1f612f532f54528079a4aa06dccd1689ae05397a05587c9af0aaa1568af2381a"
    }
  },
  {
    "ts": null,
    "headline": "MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?",
    "summary": "Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.",
    "url": "https://finnhub.io/api/news?id=5ed0b77d6dc0a36658d38ba6207ff63d9f666a1de0898608b6a6d180ab9cc564",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752502980,
      "headline": "MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?",
      "id": 135934205,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.",
      "url": "https://finnhub.io/api/news?id=5ed0b77d6dc0a36658d38ba6207ff63d9f666a1de0898608b6a6d180ab9cc564"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill",
    "summary": "RAHWAY, N.J., July 14, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse transcriptase translocation inhibitor (NRTTI) for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 (MK-8527-011, NCT 07044297) trial will evaluate the safety and efficacy of MK-8527 among people with greater likeli",
    "url": "https://finnhub.io/api/news?id=88a889f0d5b7a9f49607c30dfad72b37dada0657457ae1ace91b4bb4ce185398",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752499860,
      "headline": "Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill",
      "id": 135927548,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., July 14, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse transcriptase translocation inhibitor (NRTTI) for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 (MK-8527-011, NCT 07044297) trial will evaluate the safety and efficacy of MK-8527 among people with greater likeli",
      "url": "https://finnhub.io/api/news?id=88a889f0d5b7a9f49607c30dfad72b37dada0657457ae1ace91b4bb4ce185398"
    }
  },
  {
    "ts": null,
    "headline": "HER2+ Gastric Cancer Market Analysis and Forecast Report 2025-2035: AstraZeneca, Merck, and Roche Lead Innovation in HER2+ Gastric Cancer Therapies",
    "summary": "The global HER2+ gastric cancer market is experiencing significant growth, driven by the rising incidence of gastric cancer and increased healthcare investments. HER2-positive gastric cancer, characterized by the overexpression of the HER2 protein, leads to rapid tumor growth and metastasis. Despite advancements, challenges such as high treatment costs and limited early detection persist, affecting patient outcomes. Key players, including AstraZeneca, Merck, and Roche, are at the forefront of in",
    "url": "https://finnhub.io/api/news?id=8ebe26ad3cafc79bb93776b97470d3052715101cd1294b59991a574767387bad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752498000,
      "headline": "HER2+ Gastric Cancer Market Analysis and Forecast Report 2025-2035: AstraZeneca, Merck, and Roche Lead Innovation in HER2+ Gastric Cancer Therapies",
      "id": 135925292,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global HER2+ gastric cancer market is experiencing significant growth, driven by the rising incidence of gastric cancer and increased healthcare investments. HER2-positive gastric cancer, characterized by the overexpression of the HER2 protein, leads to rapid tumor growth and metastasis. Despite advancements, challenges such as high treatment costs and limited early detection persist, affecting patient outcomes. Key players, including AstraZeneca, Merck, and Roche, are at the forefront of in",
      "url": "https://finnhub.io/api/news?id=8ebe26ad3cafc79bb93776b97470d3052715101cd1294b59991a574767387bad"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill",
    "summary": "Merck & Co., Inc. announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse...",
    "url": "https://finnhub.io/api/news?id=1d9c9b8b6977aa369125e7e7cae7f3da0e4bc84eecdbb9fa1a84ae166a6bbe1b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752497431,
      "headline": "Merck & Co., Inc. to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill",
      "id": 135929476,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co., Inc. announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse...",
      "url": "https://finnhub.io/api/news?id=1d9c9b8b6977aa369125e7e7cae7f3da0e4bc84eecdbb9fa1a84ae166a6bbe1b"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally",
    "summary": "Merck & Co Inc: Merck to initiate phase 3 trials for investigational once-monthly HIV prevention pill Merck & Co Inc: advances MK-8527 pre-exposure prophylaxis clinical trials globally...",
    "url": "https://finnhub.io/api/news?id=9b8775cca2e83bc8505e1d7b3cecda9630f24c0c0d2b86ee9dbaad68ef68b532",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752489071,
      "headline": "Merck & Co advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally",
      "id": 135926193,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co Inc: Merck to initiate phase 3 trials for investigational once-monthly HIV prevention pill Merck & Co Inc: advances MK-8527 pre-exposure prophylaxis clinical trials globally...",
      "url": "https://finnhub.io/api/news?id=9b8775cca2e83bc8505e1d7b3cecda9630f24c0c0d2b86ee9dbaad68ef68b532"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.",
    "summary": "Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.",
    "url": "https://finnhub.io/api/news?id=af2aafb0cf42b97bac23331ec68d797ee9e274d8927b39712211af92d4fdb47c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752483060,
      "headline": "Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.",
      "id": 135948893,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.",
      "url": "https://finnhub.io/api/news?id=af2aafb0cf42b97bac23331ec68d797ee9e274d8927b39712211af92d4fdb47c"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Are Ready to Rebound. 3 to Watch Now.",
    "summary": "Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.  Large pharmaceutical companies, facing thinning pipelines, are aggressively acquiring cutting-edge biotech firms.  Notable billion-dollar deals in the past two months include the acquisition of  Verona Pharma  by Merck,  Sanofi’s   buyout of  Blueprint Medicines  and  Eli Lilly’s   purchase of  Verve Therapeutics  In a significant technical move, the ETF has recently broken out above an eight-month trend of lower highs—an important shift dating back to the start of the current administration.",
    "url": "https://finnhub.io/api/news?id=d921a7ea8f49b289f453f7c87799f0b573d2ce2df7c042968a8fea9c39cf3e8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752471000,
      "headline": "Biotech Stocks Are Ready to Rebound. 3 to Watch Now.",
      "id": 135917250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.  Large pharmaceutical companies, facing thinning pipelines, are aggressively acquiring cutting-edge biotech firms.  Notable billion-dollar deals in the past two months include the acquisition of  Verona Pharma  by Merck,  Sanofi’s   buyout of  Blueprint Medicines  and  Eli Lilly’s   purchase of  Verve Therapeutics  In a significant technical move, the ETF has recently broken out above an eight-month trend of lower highs—an important shift dating back to the start of the current administration.",
      "url": "https://finnhub.io/api/news?id=d921a7ea8f49b289f453f7c87799f0b573d2ce2df7c042968a8fea9c39cf3e8d"
    }
  }
]